Skip to main content

The Role of Baseline Blood Pressure in Guiding Treatment Choice

A Secondary Analysis of the Use of Valsartan/Hydrochlorothiazide as Initial Therapy in Hypertensive Adults in a Randomized, Double-Blind, Placebo-Controlled Trial

Clinical Drug Investigation volume 29, pages 791–802 (2009)Cite this article

Abstract

Background and Objective: Baseline blood pressure (BP) is a strong predictor of response to antihypertensive therapy and the patient’s ability to reach BP goals. The objective of this study was to evaluate the role of baseline BP as a determinant of systolic BP (SBP) and treatment outcome to assist in the choice of initial therapy.

Methods: This was a double-blind, placebo-controlled clinical trial (n = 1329) in patients with essential hypertension (mean sitting diastolic BP [DBP] ≥95 mmHg and <110 mmHg) who were randomized to placebo, valsartan 160 mg, valsartan 320 mg, hydrochlorothiazide (HCTZ) 12.5 mg, HCTZ 25 mg, valsartan/HCTZ 160 mg/12.5mg, valsartan/HCTZ 320mg/12.5mg or valsartan/HCTZ 320 mg/25 mg. Retrospective analyses were performed to determine mean BP at end of study and BP goal rates and to explore the relationship between baseline BP level and predicted final BP

Results: The final SBP and DBP were lowest in the combination therapy groups across all baseline BPs and in subgroups of patients categorized by age (≥65 years, <65 years), race/ethnicity (White, Black, other), and severity of hypertension at baseline. The proportion of patients achieving the SBP goal of <140 mmHg was highest in the valsartan/HCTZ 320 mg/25 mg group; the overall SBP goal achievement rate was 85%, and 78% of participants with stage 2 hypertension achieved goal. By comparison, 59% of patients in the HCTZ 25 mg group and 52% in the valsartan 320 mg group achieved SBP goal. Initial combination therapy was associated with lower predicted final SBP and DBP at all baseline BP levels compared with monotherapy. Analysis of tolerability data revealed that the proportion of patients experiencing dizziness or discontinuing therapy due to adverse events was generally similar across treatment groups, whereas the BP-lowering efficacy was greatest in the groups receiving combination therapy.

Conclusion: These secondary analyses suggest that characterizing the relationship between baseline SBP and achieved SBP can assist in the choice of initial therapy in a broad hypertensive population. Initial therapy with the combination of valsartan/HCTZ is more effective than monotherapy in lowering BP at all baseline BP levels, is consistent in this respect among all subgroups, and is well tolerated.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Table I
Table II
Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Chobanian AV, Bakris GL, Black HR, et al., and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6): 1206–52

    PubMed  Article  CAS  Google Scholar 

  2. Ong KL, Cheung BMY, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 2007; 49(1): 69–75

    PubMed  Article  CAS  Google Scholar 

  3. Andrade SE, Gurwitz JH, Field TS, et al. Hypertension management: the care gap between clinical guidelines and clinical practice. Am J Manag Care 2004; 10(7 Pt 2): 481–6

    PubMed  Google Scholar 

  4. Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006; 47(3): 345–51

    PubMed  Article  CAS  Google Scholar 

  5. Ardery G, Carter BL, Milchak JL, et al. Explicit and implicit evaluation of physician adherence to hypertension guidelines. J Clin Hypertens (Greenwich) 2007; 9(2): 113–9

    Article  Google Scholar 

  6. Basile J, Black HR, Flack JM, et al. The role of therapeutic inertia and the use of fixed-dose combination therapy in the management of hypertension. J Clin Hypertens (Greenwich) 2007; 9(8): 636–45

    Article  Google Scholar 

  7. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002; 62(3): 443–62

    PubMed  Article  CAS  Google Scholar 

  8. Hansson L, Zanchetti A, Carruthers SG, et al., for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351(9118): 1755–62

    PubMed  Article  CAS  Google Scholar 

  9. Lewis EJ, Hunsicker LG, Clarke WR, et al., for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12): 851–60

    PubMed  Article  CAS  Google Scholar 

  10. Cushman WC, Ford CE, Cutler JA, for the ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich) 2002; 4(6): 393–404

    Article  Google Scholar 

  11. Julius S, Kjeldsen SE, Weber M, et al., for the VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022–31

    PubMed  Article  CAS  Google Scholar 

  12. Dahlöf B, Sever PS, Poulter NR, et al., for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895–906

    PubMed  Article  Google Scholar 

  13. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 guidelines for management of arterial hypertension. J Hypertens 2007; 25 (6): 1105–87

    Google Scholar 

  14. Benz JR, Black HR, Graff A, et al. Valsartan and hydro-chlorothiazide in patients with essential hypertension: a multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12(12): 861–6

    PubMed  Article  CAS  Google Scholar 

  15. Lacourcière Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther 2005; 27(7): 1013–21

    PubMed  Article  Google Scholar 

  16. Ridker PM, Danielson E, Rifai N, et al., for the Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension 2006; 48(1): 73–9

    PubMed  Article  CAS  Google Scholar 

  17. Pool JL, Glazer R, Weinberger M, et al. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007; 29(1): 61–73

    PubMed  Article  CAS  Google Scholar 

  18. Sharma AM, Bramlage P, Kirch W. Antihypertensive effect of irbesartan and predictors of response in obesity-associated hypertension: a prospective, open-label study. Clin Drug Investig 2005; 25(12): 765–76

    PubMed  Article  CAS  Google Scholar 

  19. Mokwe E, Ohmit SE, Nasser SA, et al. Determinants of blood pressure response to quinapril in black and white hypertensive patients: the Quinapril Titration Interval Management Evaluation Trial. Hypertension 2004; 43(6): 1202–7

    PubMed  Article  CAS  Google Scholar 

  20. Materson BJ. Variability in response to antihypertensive drugs. Am J Med 2007; 120(4 Suppl. 1): S10–20

    PubMed  Article  CAS  Google Scholar 

  21. Brunner M, Cooper-DeHoff RM, Gong Y, et al., for the INVEST Investigators. Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). Am J Cardiol 2007; 99(11): 1549–54

    PubMed  Article  CAS  Google Scholar 

  22. Black HR, Levy GL, Crikelair N, et al. Predicting age- and dose-related responses to antihypertensive therapy: pooled analysis of two randomized clinical trials with valsartan alone and combined with hydrochlorothiazide. J Am Soc Hypertens 2008; 2: 476–83

    PubMed  Article  Google Scholar 

  23. Staessen JA, Thijs L, Fagard R, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004; 22(4): 847–57

    PubMed  Article  CAS  Google Scholar 

  24. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363(9426): 2049–51

    PubMed  Article  CAS  Google Scholar 

  25. Caro J, Speckman JL, Salas M, et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999; 160(1): 41–6

    PubMed  CAS  Google Scholar 

  26. Weir MR, Levy D, Crikelair N, et al. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens 2007; 20(7): 807–15

    PubMed  Article  CAS  Google Scholar 

  27. Streiner DL. Breaking up is hard to do: the heartbreak of dichotomizing continuous data. Can J Psychiatry 2002; 47(3): 262–6

    PubMed  Google Scholar 

  28. Altman DG, Royston R. The cost of dichotomizing continuous variables. BMJ 2006; 332(7549): 1080

    PubMed  Article  Google Scholar 

  29. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006; 25(1): 127–41

    PubMed  Article  Google Scholar 

  30. Mallion J-M, Carretta R, Trenkwalder P, et al., on behalf of the Co-Diovan Study Group. Valsartan/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press 2003; 12Suppl. 1: 36–43

    Article  Google Scholar 

  31. Palatini P. Combination therapy in the management of hypertension: focus on angiotensin receptor blockers combined with diuretics. J Clin Hypertens (Greenwich) 2005; 7(2): 96–101

    Article  CAS  Google Scholar 

  32. Salerno CM, Demopoulos L, Mukherjee R, et al. Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of severe hypertension. J Clin Hypertens (Greenwich) 2004; 6(11): 614–20

    Article  CAS  Google Scholar 

  33. Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension: a multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12(12): 861–6

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgements

Preparation of this manuscript was supported by Novartis Pharmaceuticals Corporation (East Hanover, NJ, USA). Dr Pool is not receiving any direct grants or honoraria, nor has any ownership in any pharmaceutical company; however, his institution, Baylor College of Medicine, receives grants from the pharmaceutical industry, which supports Dr Pool’s research programme. Robert Glazer, Nora Crikelair and Drew Levy are employees of Novartis Pharmaceuticals Corporation. Medical writing and editorial services were provided by Tanja Schub, Landmark Programs, Inc. (New York, NY, USA).

Author information

Affiliations

  1. Center for Experimental Therapeutics, Baylor College of Medicine Faculty Center, 1709 Dryden Road, Suite 632, Houston, Texas, 77030, USA

    James L. Pool

  2. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

    Robert Glazer, Nora Crikelair & Drew Levy

Authors
  1. James L. Pool
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Glazer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nora Crikelair
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Drew Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James L. Pool.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Pool, J.L., Glazer, R., Crikelair, N. et al. The Role of Baseline Blood Pressure in Guiding Treatment Choice. Clin. Drug Investig. 29, 791–802 (2009). https://doi.org/10.2165/11530600-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11530600-000000000-00000

Keywords

  • Valsartan
  • HCTZ
  • Goal Blood Pressure
  • Baseline Blood Pressure
  • Initial Combination Therapy